Gilead Sciences on Wednesday announced that the company “is aware of positive data” from a federal study of its experimental coronavirus drug, remdesivir.
Neither Gilead nor officials at the National Institute of Allergy and Infectious Diseases, sponsor of the federal research, provided further details. A spokeswoman at N.I.A.I.D., part of the National Institutes of Health, confirmed plans to make an announcement later Wednesday.
The brief announcement by Gilead read: “We understand that the trial has met its primary endpoint and that N.I.A.I.D. will provide detailed information at an upcoming briefing.”
Trading in the company’s stock was halted before the market opened.
The federal study includes 400 patients who were hospitalized with Covid-19, the illness caused by the coronavirus, and randomly assigned to take remdesivir or a placebo. Outcomes were scored on a scale ranging from recovery to death.